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Background: Little is known about COPD patients’ compliance with physical activity monitoring
and how activity relates to disease characteristics in a multi-center setting.
Methods: In a prospective study at three Northern European sites physical activity and clinical
disease characteristics were measured in 134 COPD patients (GOLD-stage IIeIV; BODE index 0
e9) and 46 controls. Wearing time, steps per day, and the physical activity level (PAL) were
measured by a multisensory armband over a period of 6 consecutive days (in total, 144h). A
valid measurement period was defined as 22 h wearing time a day on at least 5 days.
Results: The median wearing time was 142 h:17 min (99%), 141 h:1min (98%), and 142 h:24 min
(99%), respectively in the three centres. A valid measurement period was reached in 94%, 97%,
and 94% of the patients and did not differ across sites (P Z 0.53). The amount of physical
activity did not differ across sites (mean steps per day, 4725  3212, P Z 0.58; mean PAL,ithKline; ClinicalTrials.gov number, NCT00292552.
102 8881 136; fax: þ49 4102 8881 113.
esearch.de (B. Waschki).
o this work.
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Physical activity monitoring in COPD 5231.45  0.20, PZ 0.48). Multivariate linear regression analyses revealed significant associations
of FEV1, 6-min walk distance, quadriceps strength, fibrinogen, health status, and dyspnoea
with both steps per day and PAL. Previously unrecognized correlates of activity were grade
of fatigue, degree of emphysema, and exacerbation rate.
Conclusions: The excellent compliance with wearing a physical activity monitor irrespective of
study site and consistent associations with relevant disease characteristics support the use of
activity monitoring as a valid outcome in multi-center studies.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Physical activity, defined as any bodily movement produced
by the contraction of skeletal muscles that increases energy
expenditure,1 is clearly reduced in patients with COPD.2e4
Furthermore, physical inactivity has been related to
multiple important clinical outcomes in patients with COPD,
includingpoorexercise performance,2 dyspnoea,4 quadriceps
muscle weakness,2 reduced health status,5 systemic levels of
fibrinogen,6 co-existing morbidities,6,7 exacerbation-related
hospital re-admission8,9 and mortality.8,10 These findings
support the hypothesis that physical inactivity has a central
role for the downward disease spiral in patients with COPD
and may be an early cause for disease progression.11,12
Importantly, physical inactivity is potentially reversible. For
example, increased physical activity was found in patients
with COPD following an exercise-based pulmonary rehabili-
tation program,13 an exercise counselling program14 or simply
after motivational support.15 Therefore, physical activity is
an attractive outcome measure for interventional studies in
patients with COPD.
Physical activity cannot be confidently predicted from
conventional clinical descriptors of COPD.2,4,16 Moreover,
patients are not able to accurately self-report their physical
activities.17 For these reasons, it is essential to objectively
measure the patient’s physical activity using a validated
activity monitor.17,18 However, before advocating the wide-
spread use of activity monitors in the evaluation and
management of patients with COPD,19 it is important to
understand whether objective physical activity measure-
ment is feasible in patients with COPD since the compliance
in wearing an activity monitor is a conditio sine qua non for
obtaining accurate physical activity measurement.20 Data
about patients’ adherence to activity monitoring in COPD
studies are rare. Furthermore, multicentre trials investi-
gating physical activity in COPD are limited3,21 and do not
present data on the relationship between physical activity
and extrapulmonary features so far.
Therefore, the aim of our study was threefold: 1) to
investigate the compliance of COPD patients with wearing
an activity monitor, 2) to compare physical activity in COPD
patients between centres, and 3) to investigate the rela-
tionship between physical activity and clinical outcomes,
including symptoms of dyspnea and fatigue, body compo-
sition, quadriceps muscle function, functional exercise
capacity, systemic levels of fibrinogen, mood status, health
status, the degree of emphysema as determined by
computerized tomographic scanning, and exacerbation
frequency.Methods
Study design
We prospectively collected data of 134 patients with COPD
(GOLD-stage II e IV) and 46 healthy elderly control
subjects, at three study sites: CIROþ, a center of expertise
for chronic organ failure, Horn-Maastricht, the Nether-
lands; University Hospital Aintree, Liverpool, United
Kingdom; and Royal Brompton and Harefield NHS Trust,
London, United Kingdom. The study was conducted in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines. All patients provided written
informed consent, and the study was approved by the
relevant ethics and review boards.
The results from Maastricht and Liverpool were
collected during the 3-year follow up visit of the Evaluation
of COPD Longitudinally to Identify Predictive Surrogate
Endpoints (ECLIPSE) Study. The aims and operational
aspects of the ECLIPSE study have been described else-
where.22 Data in London were prospectively collected at
the same time applying the same inclusion criteria and
methodology.Physical activity
Physical activity was measured by a multisensory armband
(SenseWear, BodyMedia, Pittsburgh, PA). The SenseWear
armband was described elsewhere.3,4,23 Briefly, it incor-
porates a biaxial accelerometer and physiologic indicators
of energy expenditure. Energy expenditure estimates of the
SenseWear armband have been validated against the
doubly labeled water technique in healthy subjects24 and
against indirect calorimetry in patients with COPD.23,25
Outputs used were the wearing time, steps per day, and
physical activity level (PAL). Step counts of the SenseWear
armband showed an excellent correlation with movement
counts (vector magnitude units) derived by another vali-
dated accelerometer that is worn at the hip in 120 COPD
patients during a measurement period of one week.26 PAL
was calculated by dividing total daily energy expenditure
by sleeping metabolic rate.6,27 A PAL <1.40 indicates a very
inactive person.28
Patients and controls were asked to wear the SenseWear
Armband on 8 consecutive days, 24 h per day with the
exception of the time spent on personal hygiene. The
patients were told that the wearing time was recorded by
the armband and that the off-body duration of the armband
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plete measurement day were excluded from analyses due
to the fact that the patients had to come to the study site
which could introduce an exogenous bias.4 Therefore, the
measurement period was 6 days (maximum total: 144 h).
Previously, it has been shown that 5 measurement days of
22 h were required to reliably measure physical activity in
patients with COPD, i.e. to achieve an intra-class correla-
tion coefficient >0.8 irrespective of the weekdays.4
Therefore, we defined a valid measurement period as at
least 5 days of 22 h of measurement. Patients with <5
days were excluded from analyses.Clinical, functional, and patient-reported
characteristics
All subjects performed standardized post-bronchodilator
spirometry. The 6-min walk test (6MWT) was performed
according to the ATS guidelines.29,30 A practice 6MWT was
not completed. Subjects underwent bio-electrical imped-
ance analysis (Bodystat 1500) to measure the body
composition. Fat-free mass index was calculated using
disease-specific equations.31,32 Muscle depletion was
defined as fat-free mass index <17.05 kg/m2 in men and
<14.62 kg/m2 in women.33 Isometric quadriceps maximum
voluntary contraction strength (QMVC) was measured with
the knee joint at 90, using apparatus as described by
Edwards et al.34 Measurement techniques were standard-
ized by reciprocal visits at the start of the project. QMVC
was the highest mean force that could be sustained over
1 s. Predicted QMVC was calculated by the regression
equation described by Seymour et al.35 In Maastricht and
Liverpool, subjects underwent a low dose (120 kVp, 40 mAs)
computed tomography (CT) scan of the chest to evaluate
the severity and distribution of emphysema. CT scans were
evaluated at a central imaging unit at the University of
British Columbia. The extent of emphysema was assessed
by the percentage of lung with attenuation below 950
Hounsfield Units (HU), called Low Attenuation Area (LAA%),
using Pulmonary Workstation 2.0 software (VIDA Diagnostics
Inc., Iowa City, IA, US).
Plasma was obtained from whole blood (with EDTA as the
anticoagulant) by centrifugation (2000g, 15 min). Fibrin-
ogen was measured using an immunoturbidometric assay
validated for use with EDTA plasma (K-ASSAY fibrinogen
test, Kamiya Biomedical Co., Seattle, WA, USA). We chose
fibrinogen as a systemic inflammatory biomarker because it
is elevated in patients with COPD, is associated with poor
outcome, and has previously been related to physical
activity.6,36e38
Patient reported outcomes included assessments of
dyspnoea (modified Medical Research Council [MMRC]
Dyspnea scale) and health status (St. George’s Respiratory
Questionnaire [SGRQ]). Assessments of fatigue (Functional
Assessment of Chronic Illness Therapy - Fatigue question-
naire [FACIT-F]39) and depression (Center for Epidemiologic
Studies of Depression Scale [CES-D] were also performed.
COPD exacerbations were prospectively identified, using
a methodology which has been described previously in
detail.40 For this analysis, only moderate and severe exacer-
bations (i.e. those treated with antibiotics and/or systemiccorticosteroids or requiring hospitalization) were included.
The exacerbation rate was the number of exacerbations the
patients had experienced in the previous year to physical
activity measurement. Exacerbation rates were primarily
grouped for data analysis by none, one and two or more.
Patients were classified according to the GOLD (Global
Initiative for Chronic Obstructive Lung Disease) staging
system41 and the criteria of the BODE (body mass index,
airway obstruction, dyspnea, and exercise capacity) index.42
Statistical analyses
Descriptive data are reported as mean and standard devia-
tion (continuous variables), median and inter-quartile range
(categorical variables), or number andpercent (dichotomous
variables) as appropriate. Normal distribution was checked
with the KolmogoroveSmirnov test. Comparisons between
groups were performed with the use of analysis of variance
(ANOVA) for continuous variables, KruskaleWallis test for
categorical variables, andc2 tests fordichotomous variables.
The distribution of physical activity was analyzed across the
GOLD stages and across BODE index tertiles. To analyze the
associations between variables of physical activity and
disease characteristics univariate and multivariate linear
regression analysis were used. A P value < 0.05 was consid-
ered to be statistically significant. Data analysis were per-
formed with the Statistical Package for Social Science (SPSS;
Chicago, IL), version 16.0.
Results
Characteristics
Demographic and clinical characteristics of the COPD
patients, smoking controls, and non-smoking controls are
given in Table 1. Patients and controls did not differ in
terms of age and anthropometric characteristics. There was
a higher proportion of females among the non-smoker
controls. Maximal quadriceps force, functional exercise
capacity, and physical activity were significantly reduced in
patients with COPD compared to controls, whereas fibrin-
ogen was elevated.
Compliance with wearing an activity monitor
The median time the armband was worn and the number of
valid days of measurement according to study site are
presented in Fig. 1. During the 6-day measurement period,
the median wearing time of the armband in patients from
Maastricht, Liverpool, and London was 142 h:17min (99%),
141 h:1min (98%), and 142 h:24min (99%), respectively. A
valid measurement period of at least 5 valid days (i.e. each
day 22 h) was reached in 94% of the patients from Maas-
tricht, 97% from Liverpool, and 94% from London and did
not differ across the sites (P Z 0.53). Patients with less
than 5 days with 22 h of measurement (n Z 7) were
excluded from further analyses. The median wearing time
and the number of at least 5 valid days of measurement of
all COPD patients did not differ from those of smoking and
non-smoking controls (P Z 0.91 and 0.97, respectively).
Table 1 Demographic and clinical characteristics of COPD patients and controls.
COPD Smoking controls Non-smoking controls P value
Demographics Subject number 127 22 22
Age (yr), mean (SD) 64.6 (7.2) 68.0 (7.7) 66.4 (8.4) 0.12
Male, n (%) 79 (60.8) 12 (54.5) 7 (31.8) 0.040
Height (cm), mean (SD) 168 (8.9) 167 (8.8) 164 (9.5) 0.25
Body mass index (kg/m2), mean (SD) 26.1 (5.5) 27.5 (4.4) 24.5 (4.2) 0.18
Current smokers, n (%) 34 (26.2) 2 (9.1) 0 (0) 0.007
Pack-years, mean (SD) 38.3 (20.1) 27.2 (17.2) 0 (0) <0.001
Lung Function FEV1 (liters), mean (SD) 1.12 (0.45) 2.67 (0.80) 2.61 (0.62)
FEV1 (% of predicted), mean (SD) 41.0 (14.8) 103.0 (15.8) 107.8 (16.1)
FEV1/FVC, mean (SD) 0.40 (0.13) 0.78 (0.06) 0.78 (0.05)
Muscular Status Fat-free mass index (kg/m2), mean (SD) 17.8 (2.8) 18.8 (2.0) 17.5 (1.6) 0.17
Muscle depletion*, n (%) 36 (27.9) 0 (0) 0 (0) <0.001
QMVC (kg), mean (SD) 32.0 (13.2) 39.6 (14.7) 35.1 (10.2) 0.042
QMVC (% of predicted), mean (SD) 70.1 (20.7) 86.0 (21.2) 86.0 (17.5) <0.001
Systemic Inflammation Fibrinogen (mg/dL), mean (SD) 504 (122) 455 (129) 408 (57) 0.021
Exercise Capacity 6-min walk distance (m), mean (SD) 364 (128) 476 (132) 604 (107) <0.001
Physical Activity Steps per day, mean (SD) 4725 (3212) 10188 (4449) 10408 (3389) <0.001
Physical activity level, mean (SD) 1.45 (0.20) 1.60 (0.23) 1.66 (0.19) <0.001
* Muscle depletion was defined as fat-free mass index <17.05 kg/m
2
in men and <14.62 kg/m2 in women.
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Characteristics of COPD patients categorized according to
study site are given in Table 2. The patients’ characteristics
were similar across the sites in terms of gender, anthropo-
metrics, lung function, and systemic inflammation. COPD
patients in Maastricht were slightly younger and reported
less dyspnoea. The QMVC and the 6-min walk distance were
highest in patients from Maastricht, while patients from
Liverpool hadmore pack years of smoking and aworse health
status. The BODE index differed slightly across the sites.
Steps per day and the PAL were similar across the study
sites (Table 2). Steps per day and the PAL of smoking and non-
smoking controls did not differ across study sites (Table E1).Figure 1 Compliance with wearing an activity monitor during a m
* A valid day was a priori defined as 22 h wearing time per day.Distribution of physical activity according to
disease severity
The distribution of steps per day and the PAL according to
GOLD stages and BODE index tertiles is given in Fig. 2 A - D.
Healthy controls performed on average 10298 (3910) steps
per day and had a mean PAL of 1.63 (0.21). Even in this
group there were 8 healthy subjects (18%) who were very
inactive (i.e. PAL <1.40). In GOLD II, patients had mean
steps per day of 7139 (3520) and a mean PAL of 1.54
(0.22). Mean steps per day and PAL in GOLD stage III was
4296 (2677) and 1.42 (0.20) and in GOLD stage IV 2703
(1771) and 1.40 (0.14). A large proportion of patients in
GOLD stage III (49%) and IV (58%) were very inactive (PALeasurement period of 6 days (in total, 144 consecutive hours).
Table 2 Patients’ characteristics and physical activity according to study site.
Total Maastricht Liverpool London P value
Demographics Patient number (%) 127 (100) 58 (45.7) 37 (29.1) 32 (25.2)
Age (yr), mean (SD) 64.6 (7.2) 62.7 (7.1) 66.1 (6.0) 66.6 (8.0) 0.013
Male, n (%) 79 (60.8) 36 (60.0) 25 (65.8) 18 (56.3) 0.71
Height (cm), mean (SD) 168 (8.9) 170 (8.0) 167 (9.2) 166 (9.5) 0.069
Body mass index (kg/m2),
mean (SD)
26.1 (5.5) 26.4 (4.9) 25.9 (6.6) 25.5 (5.4) 0.76
Current smokers, n (%) 34 (26.2) 17 (28.3) 12 (31.6) 5 (15.6) 0.28
Pack-years, mean (SD) 38.3 (20.1) 36.3 (16.5) 44.7 (21.7) 34.2 (23.0) 0.056
Lung Function FEV1 (liters), mean (SD) 1.12 (0.45) 1.19 (0.52) 1.08 (0.33) 1.05 (0.42) 0.25
FEV1 (% of predicted), mean (SD) 41.0 (14.8) 41.3 (15.4) 40.9 (13.3) 40.4 (15.9) 0.96
Muscular Status Fat-free mass index (kg/m2),
mean (SD)
17.8 (2.8) 17.8 (2.6) 18.0 (3.3) 17.5 (2.4) 0.77
Muscle depletion*, n (%) 36 (27.9) 14 (23.7) 12 (31.6) 10 (31.3) 0.62
QMVC (kg), mean (SD) 32.0 (13.2) 38.7 (14.3) 26.1 (10.7) 27.8 (8.5) <0.001
QMVC (% of predicted), mean (SD) 70.1 (20.7) 82.0 (20.1) 58.4 (18.5) 63.9 (13.6) <0.001
Systemic
Inflammation
Fibrinogen (mg/dL), mean (SD) 504 (122) 504 (126) 504 (117) N/A 0.99
Exercise Capacity 6-min walk distance (m), mean (SD) 364 (128) 439 (119) 267 (81) 330 (99) <0.001
Patient-reported
Outcomes
SGRQ total score, mean (SD) 54 (18) 50 (18) 60 (14) 52 (19) 0.024
SGRQ activity score, mean (SD) 72 (19) 68 (21) 81 (12) 68 (19) 0.003
SGRQ impacts score, mean (SD) 40 (19) 37 (19) 44 (17) 39 (20) 0.22
SGRQ symptoms score, mean (SD) 65 (22) 59 (22) 72 (17) 66 (25) 0.015
MMRC dyspnoea scale, median (IQR) 2 (1e3) 1 (1e2) 2 (1e2) 2 (1e3) 0.013
CES Depression scale, mean (SD) 15.6 (9.8) 15.9 (9.8) 15.1 (10.0) N/A 0.72
CES Depression scale 16, n (%) 43 (43.9) 29 (48.3) 14 (36.8) N/A 0.26
FACIT fatigue scale, mean (SD) 30.4 (11.6) 30.4 (12.1) 30.4 (11.1) N/A 0.99
Extent of
emphysema
Low attenuation areas (%),
mean (SD)
23.2 (12.7) 23.4 (11.8) 22.9 (14.5) N/A 0.86
Exacerbations Exacerbation rate, median (IQR) 2.1 (1.0e3.3) 2.1 (1.0e3.3) 2.6 (1.0e5.1) N/A 0.18
Multidimensional
grading
BODE index, median (IQR) 4 (2e6) 3 (2e4) 4 (3e6) 5 (2e6) 0.024
Physical Activity Steps per day, mean (SD) 4725 (3212) 4556 (2828) 4559 (3729) 5240 (3279) 0.58
Physical activity level, mean (SD) 1.45 (0.20) 1.44 (0.18) 1.43 (0.20) 1.49 (0.24) 0.48
* Muscle depletion was defined as fat-free mass index <17.05 kg/m
2
in men and <14.62 kg/m2 in women.
526 B. Waschki et al.<1.40). As of GOLD stage II steps and PAL were significantly
reduced compared to healthy controls (P < 0.001 and
P Z 0.028, respectively).
Clinical correlates of physical activity in COPD
Table 3 presents univariate and multivariate linear regres-
sion analyses with steps per day and physical activity level
as the dependent variables. After adjustment for age, sex,
study site, and obesity, significant associations with both,
steps per day and PAL, could be found for FEV1, QMVC,
fibrinogen, 6-min walk distance, SGRQ (with the strongest
association for the SGRQ ‘activity’domain), MMRC dyspnoea
scale, FACIT fatigue scale, extent of emphysema, and
exacerbation rate >1 in the preceding year.
Discussion
The main findings of our study are that compliance of COPD
patients with physical activity monitoring is excellent
irrespective of study site and that physical activity
parameters are associated with clinically relevantcharacteristics in this disease. Additionally we report the
previously unrecognized correlates of physical activity and
FACIT score, CT determined extent of emphysema, and two
or more exacerbations in the preceding year. These findings
support the use of a physical activity monitor as a valid
outcome measure in multi-center studies.
Physical activity of patients with COPD has been objec-
tively measured by accelerometers or multisensory devices
in several single-center studies before.2,5,6,16,43 Most of
these studies measured physical activity over a period of
2e8 consecutive days for a median of 12e14 h per
day.2,5,16,43 Although compliance with wearing an activity
monitor is always critical to obtain accurate physical
activity measurements,20 information on patients’ adher-
ence with wearing the activity monitor during the
measurement period in COPD studies is rare. In the present
study the patients were asked to wear the armband pref-
erably 24 h a day with the exception of the time spent for
personal hygiene over a period of 6 consecutive days.
During this measurement period of 144 consecutive hours,
the median wearing time of the multisensory armband was
141 h:56min (99%) with an inter-quartile range of
139 h:51min to 142 h:53min. In other words 75% of the
Figure 2 A. Distribution of steps per day according to GOLD stages. B. Distribution of the physical activity level according to
GOLD stages. C. Distribution of steps per day according to BODE index tertiles, i.e. BODE tertile 1Z BODE score 0e2, BODE tertile
2Z BODE score 3e4, and BODE tertile 3Z BODE score 5e10. D. Distribution of the physical activity level according to BODE index
tertiles. The explanation of the BODE tertiles is redundant in legend Fig 2 D (see Fig 2 C).
Physical activity monitoring in COPD 527patients took the armband off for less than 42 min per day.
However, we found that in 21 (16%) patients the off-body
duration accumulated mainly in one day (i.e. wearing
time <22 h). The proportion of patients, who reached at
least 5 valid days with at least 22 h of measurement each,4
was still extremely high (95%). Therefore, we recommend
measurement of physical activity over a period of 6
consecutive days, which allows omission of a day of
measurement if there is an unacceptable wearing time.
So far, only two multi-center studies have measured
physical activity in patients with COPD before.3,21 Troosters
et al3 studied physical activity in 70 patients with COPD at
three study sites (Leuven, Belgium; Palermo, Italy; Pitts-
burgh, US) using the Sensewear Armband. Theirmain aimwas
to investigate the amount of physical activity across
different disease stages. Subjects were instructed to wear
the Sensewear Armband continuously (day and night) for six
to eight days. They reported that for 93% of the days, the
activity monitor was worn for more than 90% of the time.
However, compliance data were not presented according to
study site, the measurement period varied between 6 and 8
days, and instructions given to the patients were not
described in detail. As in the present report Troosters and
coworkers3 did not find significant differences in the amount
of physical activity between the sites. Pitta and colleagues21
compared the physical activity pattern of 80 patients withCOPD of two sites (Londrina, Brazil; Vienna, Austria) with
significant different socio-economic, educational, and
ethnic characteristics by an accelerometer-based activity
monitor over a measurement period of two days. They found
Austrian patients to be significantly less active than Brazil
patients. Compliance could only indirectly be inferred in this
study.21 Here we show that compliance with wearing an
activity monitor is excellent across different sites, which is
a prerequisite for the collection of reliable data in clinical
studies. Furthermore, we demonstrate that the amount of
physical activity of patients with COPD did not differ across 3
European sites, whereas exercise capacity and health status
did, which might indicate that physical activity is a more
stable disease signal of COPD when assessing outcomes in
multicentre studies.
Based on the definition of physical activity as any bodily
movement resulting in energy expenditure, we studied two
physical activity outcomes which covered both aspects:
step count (i.e. movement) and PAL (i.e. activity related
energy expenditure). We found that both physical activity
variables were reduced as of GOLD stage II compared to
healthy controls. Furthermore, we observed a higher
reduction of steps per day in very severe COPD compared to
a less pronounced reduction in PAL. This observation was
similar when patients were stratified by the BODE index.
This could be explained on the one hand by a higher energy
Figure 2 Continued.
528 B. Waschki et al.expenditure during exercise (i.e. lower mechanical effi-
ciency) in patients with severe COPD.44,45 On the other
hand Langer et al showed an underestimation of steps
measured by the SenseWear armband in patients who walk
at a very slow speed.46
Most of our current knowledge about the association of
disease characteristics with physical activity in patients
with COPD is derived from single-center studies. So far, only
the association of airflow limitation with physical activity
has been studied in a multi-center setting.3 Here we
demonstrate for the first time that exercise intolerance,
muscle dysfunction, systemic inflammation, symptoms of
dyspnoea, and an impaired health status are associated
with physical activity in patients with COPD across different
study sites. In addition, we found previously unrecognized
factors which represent relevant domains of COPD like the
degree of emphysema, frequent exacerbations (two or
more in the preceding year), and fatigue symptoms to also
be related to physical activity.
Interestingly, the association between quadriceps
muscle force and physical activity was stronger than the
association between skeletal muscle mass and physical
activity, although muscle mass and quadriceps force were
highly correlated (r Z 0.69, P < 0.001). Furthermore, we
found an association between systemic inflammation and
physical inactivity, which has been described previously.6
This association is in line with the hypothesis that regular
exercise has anti-inflammatory effects.47This study has some limitations. First, despite no
differences being observed in lung function and physical
activity across the sites, there were differences in 6-min
walk distance and QMVC between study sites, which could
have an impact on the association with physical activity.
The differences could partially be explained by the fact
that Dutch patients were taller (4 cm), younger (4 years),
had less dyspnoea, and potentially the presence of
cardiovascular comorbidities, which, however, were not
objectively assessed in this study. Nevertheless, the
association between parameters of physical activity with
these characteristics was comparable to those in other
studies2,4 after multivariate adjustments. Second, the
compliance with wearing an activity monitor was only
studied for the SenseWear armband, which is light and
requires no prior set-up by the patients in contrast to
other type of devices probably leading to worse adher-
ence. Overall, these data suggest that the SenseWear
armband may be an appropriate accelerometer to assess
physical activity in patients with COPD regardless of its
limitations which include the lack of information on time
spent walking and standing.
In conclusion, we found an excellent compliance with
wearing a physical activity monitor irrespective of study
site and stable associations with relevant disease charac-
teristics, which supports the use of physical activity moni-
tors as an outcome measure in multi-center intervention
studies. These data provide further strong evidence that
Table 3 Factors associated with steps per day and the physical activity level in uni- and multivariate linear regression analyses
in patients with COPD.














FEV1 (% of predicted) 127 0.591 <0.001 0.654 <0.001 0.373 <0.001 0.431 <0.001
Fat-free mass
index (kg/m2)b
126 0.026 0.773 0.315 0.028 0.148 0.093 0.055 0.706
QMVC (kg) 104 0.105 0.280 0.298 0.022 0.111 0.256 0.350 0.007
Fibrinogen (mg/dL) 94 0.244 0.017 0.239 0.022 0.235 0.021 0.248 0.014
6-min walk distance (m) 122 0.344 <0.001 0.472 <0.001 0.332 <0.001 0.439 <0.001
SGRQ total score 126 0.359 <0.001 0.395 <0.001 0.252 0.004 0.275 0.002
SGRQ activity score 127 0.426 <0.001 0.458 <0.001 0.310 <0.001 0.318 <0.001
SGRQ impacts score 127 0.308 <0.001 0.335 <0.001 0.220 0.012 0.242 0.005
SGRQ symptoms score 126 0.184 0.037 0.221 0.015 0.103 0.243 0.130 0.155
MMRC dyspnoea scale 127 0.317 <0.001 0.367 <0.001 0.178 0.043 0.212 0.018
CES depression scaleb 96 0.058 0.568 0.131 0.229 0.039 0.703 0.035 0.743
FACIT fatigue scale 94 0.177 0.084 0.286 0.010 0.117 0.256 0.221 0.041
Low attenuation areas (%) 86 0.418 <0.001 0.415 <0.001 0.238 0.025 0.265 0.016
Exacerbations in
preceding yr,1 vs 0
96 0.091 0.465 0.120 0.344 0.026 0.835 0.074 0.559
Exacerbations in
preceding yr,>1 vs 0
96 0.333 0.009 0.340 0.008 0.238 0.062 0.263 0.035
Fibrinogen, CES depression scale, FACIT fatigue scale, low attenuation areas, and exacerbations were only determined in Maastricht and
Liverpool.
a Multivariate regression analyses were adjusted for age, sex, study site, and BMI >30.
b Dichotomizing variables with established cut-offs, i.e. FFMI <17.05 kg/m2 in men and <14,62 kg/m2 in women and CES-D scale 16,
does not improve the associations.
Physical activity monitoring in COPD 529impaired daily activity provides an integrated measure of
the impact of many important variables in COPD.
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